## **ACC**omplishments Update

	2005	2015
Research Network	Few investigators, modest interest	50 grantees with vibrant interactions and sharing of materials and data
Biobanking	Limited	Repositories with hundreds of frozen tumor specimens
Cell Lines	Multiple invalid models	Misidentifications discovered; valid models in development
Animal Models	None	20+ mouse xenografts developed; progress in transgenic models
Genomics	Sporadic reports of translocations	<ul> <li>Discovery of MYB rearrangements and upregulation</li> <li>Identification of additional molecular targets with potential therapies: FGFR, IGF-1R, HDAC, NOTCH, TRK</li> </ul>
Preclinical Drug Screens	None in valid models	<ul> <li>Open xenograft platform for academia and industry</li> <li>Strong relationships with biopharmaceutical companies</li> <li>30 approved and 50 novel compounds screened in xenografts</li> </ul>
Mobilizing Patients	Limited	Tissue donations, clinical trial accrual and \$12 million in donations
NIH Commitments	Negligible	Over \$25MM for salivary gland tumor research (NIDCR)
Clinical Trials	Few, small & haphazard	Multiple science-driven trials with improved designs, enrollment, data quality and patient outcomes